Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.

N Engl J Med. 2005 Sep 22;353(12):1209-23. Epub 2005 Sep 19. Erratum in: N Engl J Med. 2010 Sep 9;363(11):1092-3.

2.

Quetiapine versus other atypical antipsychotics for schizophrenia.

Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S.

Cochrane Database Syst Rev. 2013 Nov 18;(11):CD006625. doi: 10.1002/14651858.CD006625.pub3. Review.

PMID:
24249315
3.

Ziprasidone versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PS, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006627. doi: 10.1002/14651858.CD006627.pub2. Review.

4.

Quetiapine versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, Srisurapanont M, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006625. doi: 10.1002/14651858.CD006625.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;11:CD006625.

5.

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.

Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S.

Schizophr Res. 2010 Nov;123(2-3):225-33. doi: 10.1016/j.schres.2010.07.012. Epub 2010 Aug 7. Review.

6.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
7.

[Current pharmacotherapy of schizophrenia].

Bitter I.

Orv Hetil. 2004 Jan 18;145(3):105-9. Review. Hungarian.

PMID:
15027331
8.

Atypical antipsychotics: newer options for mania and maintenance therapy.

Vieta E, Goikolea JM.

Bipolar Disord. 2005;7 Suppl 4:21-33. Review.

PMID:
15948764
9.

The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.

Citrome L, Volavka J.

Postgrad Med. 2004 Oct;116(4):49-51, 55-9, 63. Review.

PMID:
15510593
10.

Ziprasidone: a new atypical antipsychotic.

Keck PE Jr, McElroy SL, Arnold LM.

Expert Opin Pharmacother. 2001 Jun;2(6):1033-42. Review.

PMID:
11585006
11.

Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder.

Lorenz RA, Jackson CW, Saitz M.

Pharmacotherapy. 2010 Sep;30(9):942-51. doi: 10.1592/phco.30.9.942. Review.

PMID:
20795849
12.

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

Correll CU, Leucht S, Kane JM.

Am J Psychiatry. 2004 Mar;161(3):414-25. Review.

PMID:
14992963
13.

New antipsychotics and schizophrenia: a review on efficacy and side effects.

Serretti A, De Ronchi D, Lorenzi C, Berardi D.

Curr Med Chem. 2004 Feb;11(3):343-58. Review.

PMID:
14965236
14.

Comparing the side effect profile of the atypical antipsychotics.

Alao AO, Malhotra K, Dewan MJ.

West Afr J Med. 2002 Oct-Dec;21(4):313-5. Review.

PMID:
12665274
15.

Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.

Soares-Weiser K, Béchard-Evans L, Lawson AH, Davis J, Ascher-Svanum H.

Eur Neuropsychopharmacol. 2013 Feb;23(2):118-25. doi: 10.1016/j.euroneuro.2012.05.001. Epub 2012 May 26. Review.

PMID:
22633617
16.

Atypical antipsychotics in the management of delirium: a review of the empirical literature.

Boettger S, Breitbart W.

Palliat Support Care. 2005 Sep;3(3):227-37. Review.

PMID:
16594462
17.

Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.

McDougle CJ, Stigler KA, Erickson CA, Posey DJ.

J Clin Psychiatry. 2008;69 Suppl 4:15-20. Review.

18.

Treatment of bipolar disorder: the evolving role of atypical antipsychotics.

Perlis RH.

Am J Manag Care. 2007 Nov;13(7 Suppl):S178-88. Review. Erratum in: Am J Manag Care. 2008 Feb;14(2):76.

PMID:
18041879
19.

Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions.

Raggi MA, Mandrioli R, Sabbioni C, Pucci V.

Curr Med Chem. 2004 Feb;11(3):279-96. Review.

PMID:
14965232
20.

Review of atypical antipsychotics and weight gain.

Sussman N.

J Clin Psychiatry. 2001;62 Suppl 23:5-12. Review.

Supplemental Content

Support Center